On behalf of the WP5 Sharon McHale & Riia Järvenpää DRIVE Annual Forum 17th -18th September 2018, Rome

1. Dissemination of
Pilot Year Outcomes
Communications Workshop
Work Package 5
DRIVE Annual Forum
18 September 2018

2. • WP5 introductions
• DRIVE communication channels
• High-level dissemination plan
• Q&A
• Group Activity
• Group Presentations
• Wrap-Up
Agenda

3. DRIVE Website at www.drive-eu.org
• Features all public deliverables
• Information on Data source, Methodology, Governance model,
Analytical model and Infrastructure of the project

4. DRIVE on LinkedIn:
https://www.linkedin.com/company
/drive-project/

5. DRIVE at Twitter: @drive_eu
#DRIVEflu

6. Web-based survey of PHIs & PHAs
N=7 to date
Current IVE communications adequate: >50% yes
Additional IVE info required: age/risk, type, brand
Recommended communication channels: conferences,
publications, direct, news releases, websites, social media
Frequency: regular/monthly about DRIVE activities
Intention to share DRIVE results with stakeholders: yes
Concerns: 1 about PPP, 1 about reconciliation of DRIVE findings
with findings of other IVE studies
Communications Survey

7. DRIVE Stakeholders
DRIVE
IMI
European
Science,
Medicine &
Health
Societies
Society at large
ECDC
WHO
EMA
CHMP
Vaccine
Manufacturers
Public Health
Institutes
National
Health
Agencies
European
Commission
European
Patient &
Consumer
Health
Groups
European
Medical &
Nursing
Schools
HCPs
Layer 3
Layer 1
European
Influenza
experts
Research
Partners &
Collaborators
Media
Layer 2

8. Dissemination Objectives
Primary Objective
Ensure pilot year outcomes are communicated in a
meaningful way to all stakeholder groups
Secondary Objectives
1. Fulfil DRIVE’s commitment to transparency
2. Strengthen the profile and credibilty of DRIVE as public-
private partnership dedicated to brand-specific IVE
3. Recruit additional research partners to DRIVE
4. Stimulate scientific discussion about innovative
approaches to IVE research and potential synergies

9. Communications Challenges
1. Diverse technical understanding of stakeholders
2. Potential for misinterpretation of IVE estimates
3. Perception of public-private partnerships
3. Uncoordinated disemmination of outcomes

10. Key Messages
1. DRIVE is an IMI-funded public private partnership
established in 2017 to build a sustainable platform for
generating robust brand-specific influenza vaccine
effectiveness data across Europe each year, as part of
new EMA requirements.
2. DRIVE has established Project Governance, including an
independent scientific review process, and an initial
study platform, which was successfully tested through a
pilot study in the 2017/18 season.
3. DRIVE calls for additional research partners to
contribute data and expertise, enabling the Project to
continue to improve the study platform and to work
towards its longer term goal.

11. • Study Reports and Summaries
• Results Slide Presentation & Poster
• Infographics
Key Communication Tools

12. DRIVE Infographic

13. High Level Plan
Annual
Forum
Sept 17-18
Present Outcomes
Seek feedback on
Communications
approach
Execute Social
Media Plan
Study Reports
Finalised
October
ESCAIDE
Host webinars
Direct email to
Stakeholders
Issues New Release
Load reports onto
DRIVE website
Execute Social
Media Plan
Conferences &
Publications
2019
Direct approach to
potential partners

14. Annual pooled brand-specific IVE estimates
Systematic review on bias & confounders
Availability & use of brand information
Laboratory methods
Other methodological topics (sample size, pooling
approaches etc.)
The rationale of brand-specific IVE and PPP governance
Scientific independence, intergrity & transparency
Potential publications

15. Q&A

16. Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
Communications –
Interactive session
Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
Gael Dos Santos - GSK
18th September 2018, Rome

17. Instructions
• Each group will brainstorm for 30’ to discuss what your
stakeholder group would like to know from DRIVE
about IVE.
• Prepare a few bullet points for presentation highlighting
the key points.
• Each group will have a slot of 5’ divided as follows:
• At the beginning of the work, each group need to
assign:
- One time keeper
- One scribe/presenter
- The facilitators for each group have been identified
on the list.

18. Assigned groups
1. Regulatory Authorities – Pieter Neels
2. Public Health Institutes (PHI)/ National and supranational
public health organisations Caterina Rizzo
3. Health Care Professionals - Topi Turunen
4. Researchers/Scientists Group 1 - Margarita Riera
5. Researchers/Scientists Group 2 - Marianne Van der Sande
6. Patients/Patient Organisations - Sam Nye
7. Media - Julien Guyomard

19. Questions to consider?
- What would I like to know about the DRIVE IVE
and when?
- Are there any particular sensitivities/issues/risks
about communicating to my stakeholder?
- Does the Public Private Partnership matter?
Why?

20. Questions/proposals